Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 52-week Treatment, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (300 and 600 µg Once Daily) in Patients With Chronic Obstructive Pulmonary Disease, Using Formoterol (12 µg Twice Daily) as an Active Control
Brief Summary: This study was designed to assess the efficacy and long-term safety of 300 and 600 µg doses of indacaterol when delivered via a single-dose dry-powder inhaler (SDDPI) in patients with chronic obstructive pulmonary disease (COPD). Patients were randomized to receive either indacaterol 300 µg once daily, indacaterol 600 µg once daily, formoterol 12 µg twice daily, or placebo.


Options:
A: Arm Label: Tiotropium + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium bromide, Drug: Placebo Salmeterol | Arm Label: Salmeterol + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol, Drug: Placebo Tiotropium | Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Salmeterol + Placebo | Intervention Type: DRUG; Name: Placebo Salmeterol; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Placebo Tiotropium; Assigned to Arm(s): Salmeterol + Placebo
B: Arm Label: Indacaterol; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 µg | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium | Intervention Type: DRUG; Name: Indacaterol 150 µg; Assigned to Arm(s): Indacaterol | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium
C: Arm Label: Indacaterol 300 μg plus placebo to formoterol; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Placebo to formoterol | Arm Label: Indacaterol 600 μg plus placebo to formoterol; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Placebo to formoterol | Arm Label: Formoterol 12 μg plus placebo to indacaterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol, Drug: Placebo to indacaterol | Arm Label: Placebo to indacaterol plus placebo to formoterol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to indacaterol, Drug: Placebo to formoterol | Intervention Type: DRUG; Name: Indacaterol; Assigned to Arm(s): Indacaterol 300 μg plus placebo to formoterol, Indacaterol 600 μg plus placebo to formoterol | Intervention Type: DRUG; Name: Formoterol; Assigned to Arm(s): Formoterol 12 μg plus placebo to indacaterol | Intervention Type: DRUG; Name: Placebo to indacaterol; Assigned to Arm(s): Formoterol 12 μg plus placebo to indacaterol, Placebo to indacaterol plus placebo to formoterol | Intervention Type: DRUG; Name: Placebo to formoterol; Assigned to Arm(s): Indacaterol 300 μg plus placebo to formoterol, Indacaterol 600 μg plus placebo to formoterol, Placebo to indacaterol plus placebo to formoterol
D: Arm Label: Relovair; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI) | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium | Intervention Type: DRUG; Name: fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI); Assigned to Arm(s): Relovair | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium

Answer: C